Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GAINESVILLE, Fla., Aug. 4, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC) announced today the closing on July 30, 2014 of its public offering of 2,000,000 shares of its common stock at a price to the public of $15.00 per share, before underwriting discounts, and the
View HTML
Toggle Summary AGTC Announces Pricing of Public Offering
GAINESVILLE, Fla., July 24, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC) today announced the pricing of its public offering of 2,000,000 shares of its common stock at a price to the public of $15.00 per share, before underwriting discounts.
View HTML
Toggle Summary AGTC Appoints Matthew Feinsod, MD, as Product Development Officer
Development, Clinical, and Regulatory Expertise Will Support Advancement of AGTC's Product Portfolio
View HTML
Toggle Summary AGTC Appoints David R. Guyer, MD, and Ivana Magovcevic-Liebisch, PhD, JD, to Its Board of Directors
GAINESVILLE, Fla., June 30, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that it has appointed David R.
View HTML
Toggle Summary AGTC and SAFC Create Strategic Partnership to Provide Gene Therapy Manufacturing Services
GAINESVILLE, Fla. and CARLSBAD, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, and SAFC Commercial (SAFC),
View HTML
Toggle Summary AGTC to Present at Upcoming Investor Conferences
GAINESVILLE, Fla., June 5, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will
View HTML
Toggle Summary AGTC Announces Financial Results for the Quarter and Nine Months Ended March 31, 2014
GAINESVILLE, Fla., May 14, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the three and
View HTML
Toggle Summary AGTC Data Presented at the ARVO Annual Meeting Support Development of Gene-Based Therapies for Achromatopsia
GAINESVILLE, Fla., May 5, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, announced that Guo-jie Ye, Ph.
View HTML
Toggle Summary AGTC Announces Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
GAINESVILLE, Fla. , May 2, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Guo-jie Ye , Ph.
View HTML
Toggle Summary AGTC Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GAINESVILLE, Fla., April 3, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC) announced today the closing on April 1, 2014 of its initial public offering of 4,166,667 shares of its common stock at an initial public offering price of $12.00 per share, and the exercise
View HTML
Visionary science for life changing cures.